Malta - englanti - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - hydrocortisone acetate, benzyl benzoate, bismuth subgallate, bismuth oxide, balsam peru, zinc oxide - ointment - hydrocortisone acetate 0.25 g benzyl benzoate 1.25 g bismuth subgallate 2.25 g bismuth oxide 0.875 g balsam peru 1.875 g zinc oxide 10.75 g - vasoprotectives

Malta - englanti - Medicines Authority

neofarma pharmaceuticals limited 42-46, mill street, qormi, qrm 3105, malta - hydrocortisone acetate, benzyl benzoate, bismuth subgallate, bismuth oxide, balsam peru, zinc oxide - suppository - hydrocortisone acetate 10 mg benzyl benzoate 33 mg bismuth subgallate 59 mg bismuth oxide 24 mg balsam peru 49 mg zinc oxide 296 mg - vasoprotectives

Arabiemiirikunnat - englanti - MOHAP (Ministry of Health & Prevention) - وزارة الصحة ووقاية المجتمع.الإمارات

royal pharmaceutical drug store llc united states of america - 1 device unit [2700] - device - device - n/a

Euroopan unioni - englanti - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - telmisartan, hydrochlorothiazide - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.micardisplus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.micardisplus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on micardisplus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

united pharmacists coop ltd - panax ginseng retinol colecalciferol tocopherol (all-rac-a), vitamin e ascorbic acid thiamine mononitrate riboflavin nicotinamide pyridoxine hydrochloride folic acid cyanocobalamin biotin anhydrous dibasic calcium phosphate ferrous sulfate magnesium sulfate dried zinc sulfate copper sulfate sodium selenite anhydrous lecithin - capsules, soft

Australia - englanti - Department of Health (Therapeutic Goods Administration)

universal pharmaceuticals pty ltd - zinc amino acid chelate, quantity: 15 mg (equivalent: zinc, qty 3 mg); vaccinium myrtillus, quantity: 100 mg (equivalent: vaccinium myrtillus, qty 10 g); ginkgo biloba, quantity: 20 mg (equivalent: ginkgo biloba, qty 1000 mg; equivalent: ginkgolides and bilobalide, qty 1.2 mg; equivalent: ginkgo flavonglycosides, qty 4.8 mg); riboflavin, quantity: 25 mg; hesperidin, quantity: 50 mg; taurine, quantity: 50 mg; glutamine, quantity: 25 mg; natural fish oil, quantity: 500 mg (equivalent: eicosapentaenoic acid, qty 80 mg; equivalent: docosahexaenoic acid, qty 50 mg); ascorbic acid, quantity: 200 mg; euphrasia officinalis, quantity: 30 mg (equivalent: euphrasia officinalis, qty 120 mg); d-alpha-tocopherol, quantity: 134.2 mg; copper gluconate, quantity: 3.57 mg (equivalent: copper, qty 500 microgram); tagetes erecta, quantity: 66.67 mg (equivalent: tagetes erecta, qty 500.025 mg; equivalent: lutein esters calculated as lutein (of tagetes erecta), qty 5.0002 mg); betacarotene, quantity: 2.502 mg - capsule, soft - excipient ingredients: silicon dioxide; gelatin; iron oxide black; purified water; glycerol; yellow beeswax; colloidal anhydrous silica; soya oil; mixed (low-alpha type) tocopherols concentrate; lecithin; ascorbyl palmitate - antioxidant/reduce free radicals formed in the body ; helps maintain/support eye macula health ; helps maintain/support eye retina health ; aids/assists eye adaption to variations in light intensity/night vision ; maintain/support healthy eyesight/vision ; maintain/support healthy blood circulation ; maintain/support blood capillary health

Australia - englanti - Department of Health (Therapeutic Goods Administration)

universal pharmaceuticals pty ltd - zinc amino acid chelate, quantity: 15 mg (equivalent: zinc, qty 3 mg); d-alpha-tocopherol, quantity: 134.2 mg; vaccinium myrtillus, quantity: 100 mg (equivalent: vaccinium myrtillus, qty 10 g); taurine, quantity: 50 mg; hesperidin, quantity: 50 mg; natural fish oil, quantity: 500 mg (equivalent: docosahexaenoic acid, qty 50 mg; equivalent: eicosapentaenoic acid, qty 80 mg); ginkgo biloba, quantity: 20 mg (equivalent: ginkgo biloba, qty 1000 mg; equivalent: ginkgo flavonglycosides, qty 4.8 mg; equivalent: ginkgolides and bilobalide, qty 1.2 mg); ascorbic acid, quantity: 200 mg; glutamine, quantity: 25 mg; riboflavin, quantity: 25 mg; copper gluconate, quantity: 3.57 mg (equivalent: copper, qty 500 microgram); euphrasia officinalis, quantity: 30 mg (equivalent: euphrasia officinalis, qty 120 mg); betacarotene, quantity: 2.502 mg; tagetes erecta, quantity: 66.67 mg (equivalent: tagetes erecta, qty 500.025 mg; equivalent: lutein esters calculated as lutein (of tagetes erecta), qty 5.0002 mg) - capsule, soft - excipient ingredients: lecithin; iron oxide black; mixed (low-alpha type) tocopherols concentrate; yellow beeswax; purified water; soya oil; gelatin; silicon dioxide; colloidal anhydrous silica; glycerol; ascorbyl palmitate - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; maintain/support healthy eye function ; maintain/support eye health ; helps maintain/support eye macula health ; helps maintain/support eye retina health ; aids/assists eye adaption to variations in light intensity/night vision ; maintain/support healthy eyesight/vision

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - isoleucine; leucine; lysine hydrochloride; methionine; phenylalanine; threonine; tryptophan; valine; arginine; histidine hydrochloride monohydrate; alanine; glycine ph. eur; aspartic acid; glutamic acid; proline; serine; sodium hydroxide; sodium chloride; sodium acetate trihydrate; potassium acetate; magnesium acetate trihydrate; calcium chloride dihydrate; glucose monohydrate; sodium dihydrogen phosphate dihydrate; zinc acetate dihydrate; triglycerides, medium chain; soya bean oil, refined ph. eur.; omega- - emulsion for infusion - solutions for parenteral nutrition; combinations

Irlanti - englanti - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - isoleucine; leucine ; lysine hydrochloride; methionine; phenylalanine; threonine; tryptophan; valine; arginine ; histidine hydrochloride monohydrate; alanine; aspartic acid; glutamic acid ; glycine; proline; serine; sodium hydroxide ; sodium chloride; potassium acetate; magnesium acetate tetrahydrate; calcium chloride dihydrate; glucose monohydrate; sodium dihydrogen phosphate dihydrate; zinc acetate dihydrate; triglycerides, medium chain; omega-3-acid triglycerides - emulsion for infusion - unknown - solutions for parenteral nutrition; combinations

Euroopan unioni - englanti - EMA (European Medicines Agency)

teva pharma b.v.  - clopidogrel (as hydrobromide) - peripheral vascular diseases; acute coronary syndrome; myocardial infarction; stroke - antithrombotic agents - prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome: non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy.prevention of atherothrombotic and thromboembolic events in atrial fibrillationin adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke.